Pharmacologic Management of Type 2 Diabetes

Canadian Journal of Diabetes

Volumn 37, Issue SUPPL.1, 2013, Pages

  Harper, William ^a   Clement, Maureen ^a   Goldenberg, Ronald ^a   Hanna, Amir ^a   Main, Andrea ^a   Retnakaran, Ravi ^a   Sherifali, Diana ^a   Woo, Vincent ^a   Yale, Jean François ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACARBOSE; ALPHA GLUCOSIDASE INHIBITOR; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; GLIMEPIRIDE PLUS ROSIGLITAZONE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; INSULIN; INSULIN ASPART; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN GLULISINE; INSULIN LISPRO; ISOPHANE INSULIN; LINAGLIPTIN; LINAGLIPTIN PLUS METFORMIN; LIRAGLUTIDE; METFORMIN; METFORMIN PLUS ROSIGLITAZONE; METFORMIN PLUS SITAGLIPTIN; NATEGLINIDE; ORAL ANTIDIABETIC AGENT; PIOGLITAZONE; REPAGLINIDE; SAXAGLIPTIN; SITAGLIPTIN; SULFONYLUREA; UNINDEXED DRUG; ANTIDIABETIC AGENT;

ANTIDIABETIC ACTIVITY; ARTICLE; BEDTIME DOSAGE; BLADDER CANCER; CELL HYPERPLASIA; CONGESTIVE HEART FAILURE; CYANOCOBALAMIN DEFICIENCY; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG SAFETY; EDEMA; FRACTURE; GASTROINTESTINAL DISEASE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; NAUSEA AND VOMITING; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREATITIS; PARAFOLLICULAR CELL HYPERPLASIA; PREVALENCE; RETINA MACULA EDEMA; SIDE EFFECT; TREATMENT DURATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN; CANADA; DIABETES MELLITUS, TYPE 2; HYPERGLYCEMIA; PRACTICE GUIDELINE;

CANADA; DIABETES MELLITUS, TYPE 2; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; METFORMIN;

EID: 84876062008     PISSN: 14992671     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcjd.2013.01.021     Document Type: Article

References (111)

1. Turner R.C., Cull C.A., Frighi V., et al. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). JAMA 1999, 281:2005-2012.
2. Klein R., Klein B.E., Moss S.E., et al. The Wisconsin epidemiological study of diabetic retinopathy. III. Prevalence and risk of diabetic retinopathy when age at diagnosis is 30 or more years. Arch Ophthalmol 1984, 102:527-532.
3. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998, 352:837-853. UK Prospective Diabetes Study (UKPDS) Group.
4. Bloomgarden Z.T., Dodis R., Viscoli C.M., et al. Lower baseline glycemia reduces apparent oral agent glucose-lowering efficacy: a meta-regression analysis. Diabetes Care 2006, 29:2137-2139.
5. Sherifali D., Nerenberg K., Pullenayegum E., et al. The effect of oral antidiabetic agents on A1C levels: a systematic review and meta-analysis. Diabetes Care 2010, 33:1859-1864.
6. Monnier L., Lapinski H., Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c). Diabetes Care 2003, 26:881-885.
7. Chiasson J.-L., Josse R.G., Hunt J.A., et al. The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus. A multicenter controlled clinical trial. Ann Intern Med 1994, 121:928-935.
8. Aschner P., Kipnes M.S., Lunceford J.K., et al. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 2006, 29:2632-2637.
9. Charbonnel B., Karasik A., Liu J., et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care 2006, 29:2638-2643.
10. Weiss S.R., Cheng S.L., Kourides I.A., et al. Inhaled insulin provides improved glycemic control in patients with type 2 diabetes mellitus inadequately controlled with oral agents: a randomized controlled trial. Arch Intern Med 2003, 27:2277-2282. Inhaled Insulin Phase II Study Group.
11. Dailey G., Rosenstock J., Moses R.G., et al. Insulin glulisine provides improved glycemic control in patients with type 2 diabetes. Diabetes Care 2004, 27:2363-2368.
12. Roach P., Yue L., Arora V. Improved postprandial glycemic control during treatment with Humalog Mix25, a novel protamine-based insulin lispro formulation. Humalog Mix25 Study Group. Diabetes Care 1999, 22:1258-1261.
13. Boehm B.O., Home P.D., Behrend C., et al. Premixed insulin aspart 30 vs. premixed human insulin 30/70 twice daily: a randomized trial in type 1 and type 2 diabetic patients. Diabet Med 2002, 19:393-399.
14. Ahren B., Gomis R., Standl E., et al. Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes. Diabetes Care 2004, 27:2874-2880.
15. Derosa G., Mugellini A., Ciccarelli L., et al. Comparison between repaglinide and glimepiride in patients with type 2 diabetes mellitus: a one-year, randomized, double-blind assessment of metabolic parameters and cardiovascular risk factors. Clin Ther 2003, 25:472-484.
16. Ristic S., Collober-Maugeais C., Pecher E., et al. Comparison of nateglinide and gliclazide in combination with metformin, for treatment of patients with Type 2 diabetes mellitus inadequately controlled on maximum doses of metformin alone. Diabet Med 2006, 23:757-762.
17. Ross S.A., Zinman B., Campos R.V., et al. A comparative study of insulin lispro and human regular insulin in patients with type 2 diabetes mellitus and secondary failure of oral hypoglycemic agents. Clin Invest Med 2001, 24:292-298.
18. Rosenfalck A.M., Thorsby P., Kjems L., et al. Improved postprandial glycaemic control with insulin aspart in type 2 diabetic patients treated with insulin. Acta Diabetol 2000, 37:41-46.
19. Sumeet R., Singh S.R., Ahmad F., et al. Efficacy and safety of insulin analogues for the management of diabetes mellitus: a meta-analysis. CMAJ 2009, 180:385-397.
20. Mannucci E., Monami M., Marchionni N. Short-acting insulin analogues vs. regular human insulin in type 2 diabetes: a meta-analysis. Diabetes Obes Metab 2009, 11:53-59.
21. Raz I., Wilson P.W., Strojek K., et al. Effects of prandial versus fasting glycemia on cardiovascular outcomes in type 2 diabetes: the HEART2D trial. Diabetes Care 2009, 32:381-386.
22. Garber A.J., Larsen J., Schneider S.H., et al. Simultaneous glyburide/metformin therapy is superior to component monotherapy as an initial pharmacological treatment for type 2 diabetes. Diabetes Obes Metab 2002, 4:201-208.
23. Rosenstock J., Goldstein B.J., Vinik A.I., et al. Effect of early addition of rosiglitazone to sulphonylurea therapy in older type 2 diabetes patients (>60 years): the Rosiglitazone Early vs. Sulphonylurea Titration (RESULT) study. Diabetes Obes Metab 2006, 8:49-57.
24. Rosenstock J., Rood J., Cobitz A., et al. Improvement in glycaemic control with rosiglitazone/metformin fixed-dose combination therapy in patients with type 2 diabetes with very poor glycaemic control. Diabetes Obes Metab 2006, 8:643-649.
25. Rosenstock J., Rood J., Cobitz A., et al. Initial treatment with rosiglitazone/metformin fixed-dose combination therapy compared with monotherapy with either rosiglitazone or metformin in patients with uncontrolled type 2 diabetes. Diabetes Obes Metab 2006, 8:650-660.
26. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998, 352:854-865. UK Prospective Diabetes Study (UKPDS) Group.
27. Boussageon R., Supper I., Bejan-Angoulvant T., et al. Reappraisal of metformin efficacy in the treatment of type 2 diabetes: a meta-analysis of randomised controlled trials. PLoS Med 2012, 9:e1001204.
28. Kahn S.E., Haffner S.M., Heise M.A., et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006, 355:2427-2443.
29. Meymeh R.H., Wooltorton E. Diabetes drug pioglitazone (Actos): risk of fracture. CMAJ 2007, 177:723-724.
30. Kahn S.E., Zinman B., Lachin J.M., et al. Rosiglitazone-associated fractures in type 2 diabetes: an analysis from A Diabetes Outcome Progression Trial. Diabetes Care 2008, 31:845-851. A Diabetes Outcome Progression Trial (ADOPT) Study Group.
31. Nissen S.E., Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007, 356:2457-2471.
32. Nissen S.E., Wolski K. Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality. Arch Intern Med 2010, 170:1191-1201.
33. Home P.D., Pocock S.J., Beck-Nielsen H., et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet 2009, 373:2125-2135.
34. Home P.D., Pocock S.J., Beck-Nielsen H., et al. Rosiglitazone evaluated for cardiovascular outcomes: an interim analysis. N Engl J Med 2007, 357:28-38.
35. Dormandy J.A., Charbonnel B., Eckland D.J., et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005, 366:1279-1289.
36. Lincoff A.M., Wolski K., Nicholls S.J., Nissen S.E. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA 2007, 298:1180-1188.
37. Liu S.C., Tu Y.K., Chien K.L. Effect of antidiabetic agents added to metformin on glycemic control, hypoglycemia, and weight change in patients with type 2 diabetes: a network meta-analysis. Diabetes Obes Metab 2012, 14:810-820.
38. Ray K.K., Seshasai S.R., Wijesuriya S., et al. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet 2009, 373:1765.
39. Kelly T.N., Bazzano L.A., Fonseca V.A., et al. Systematic review: glucose control and cardiovascular disease in type 2 diabetes. Ann Intern Med 2009, 151:394.
40. Boussageon R., Bejan-Angoulvant T., Saadatian-Elahi M., et al. Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials. BMJ 2011, 343:d4169.
41. Chiasson J.L., Josse R.G., Gomis R., et al. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA 2003, 290:486-494. STOP-NIDDM Trial Research Group.
42. Gaziano J.M., Cincotta A.H., O'Connor C.M., et al. Randomized clinical trial of quick-release bromocriptine among patients with type 2 diabetes on overall safety and cardiovascular outcomes. Diabetes Care 2010, 33:1503-1508.
43. Frederich R., Alexander J.H., Fiedorek F.T., et al. A systematic assessment of cardiovascular outcomes in the saxagliptin drug development program for type 2 diabetes. Postgrad Med 2010, 122:16-27.
44. Monami M., Cremasco F., Caterina L., et al. Glucagon-like peptide-1 receptor agonists and cardiovascular events: a meta-analysis of randomized clinical trials. Exp Diabetes Res 2011, 2011:215764.
45. Amori R.E., Lau J., Pittas A.G. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA 2007, 298:194-206.
46. Fakhoury W.K., Lereun C., Wright D. A meta-analysis of placebo-controlled clinical trials assessing the efficacy and safety of incretin-based medications in patients with type 2 diabetes. Pharmacology 2010, 86:44-57.
47. Monami M., Marchionni N., Mannucci E. Glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized clinical trials. Eur J Endocrinol 2009, 160:909-917.
48. Pinelli N.R., Cha R., Brown M.B., Jaber L.A. Addition of thiazolidinedione or exenatide to oral agents in type 2 diabetes: a meta-analysis. Ann Pharmacother 2008, 42:1541-1551.
49. Yki-Järvinen H., Kauppila M., Kujansuu E., et al. Comparison of insulin regimens in patients with non-insulin-dependent diabetes mellitus. N Engl J Med 1992, 327:1426-1433.
50. Rosenstock J., Schwartz S.L., Clark C.M., et al. Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin. Diabetes Care 2001, 24:631-636.
51. Johnson J.L., Wolf S.L., Kabadi U.M. Efficacy of insulin and sulfonylurea combination therapy in type II diabetes. A metaanalysis of the randomized placebo-controlled trials. Arch Intern Med 1996, 156:259-264.
52. United Kingdom Prospective Diabetes Study 24: a 6-year, randomized, controlled trial comparing sulfonylurea, insulin, and metformin therapy in patients with newly diagnosed type 2 diabetes that could not be controlled with diet therapy. Ann Intern Med 1998, 128:165-175. United Kingdom Prospective Diabetes Study Group.
53. Yki-Järvinen H., Ryysy L., Nikkilä K., et al. Comparison of bedtime insulin regimens in patients with type 2 diabetes mellitus. A randomized, controlled trial. Ann Intern Med 1999, 130:389-396.
54. Tan A., Cao Y., Xia N., et al. The addition of pioglitazone in type 2 diabetics poorly controlled on insulin therapy: a meta-analysis. Eur J Intern Med 2010, 21:398-403.
55. Buse J.B., Bergenstal R.M., Glass L.C., et al. Use of twice-daily exenatide in basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial. Ann Intern Med 2011, 154:103-112.
56. Arnolds S., Dellweg S., Clair J., et al. Further improvement in postprandial glucose control with addition of exenatide or sitagliptin to combination therapy with insulin glargine and metformin: a proof-of-concept study. Diabetes Care 2010, 33:1509-1515.
57. Barnett A.H., Charbonnel B., Donovan M., et al. Effect of saxagliptin as add-on therapy in patients with poorly controlled type 2 diabetes on insulin alone or insulin combined with metformin. Curr Med Res Opin 2012, 28:513-523.
58. Vilsboll T., Rosenstock J., Yki-Jarvinen H., et al. Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes. Diabetes Obes Metab 2010, 12:167-177.
59. American Diabetes Association Implications of the United Kingdom Prospective Diabetes Study. Diabetes Care 1998, 21:2180-2184.
60. Gerstein H.C., Bosch J., Dagenais G.R., et al. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med 2012, 367:319-328. ORIGIN Trial Investigators.
61. Gerstein H.C., Yale J.F., Harris S.B., et al. A randomized trial of adding insulin glargine vs. avoidance of insulin in people with Type 2 diabetes on either no oral glucose-lowering agents or submaximal doses of metformin and/or sulphonylureas. The Canadian INSIGHT (Implementing New Strategies with Insulin Glargine for Hyperglycaemia Treatment) Study. Diabet Med 2006, 23:736-742.
62. Abraira C., Colwell J.A., Nuttall F.Q., et al. Veterans Affairs Cooperative Study on glycemic control and complications in type II diabetes (VA CSDM). Results of the feasibility trial. Diabetes Care 1995, 18:1113-1123.
63. Holman R.R., Farmer A.J., Davies M.J., et al. Three-year efficacy of complex insulin regimens in type 2 diabetes. N Engl J Med 2009, 361:1736-1747.
64. Bretzel R.G., Nuber U., Landgraf W., et al. Once-daily basal insulin glargine versus thrice-daily prandial insulin lispro in people with type 2 diabetes on oral hypoglycaemic agents (APOLLO): an open randomised controlled trial. Lancet 2008, 371:1073-1084.
65. Wulffelé M.G., Kooy A., Lehert P., et al. Combination of insulin and metformin in the treatment of type 2 diabetes. Diabetes Care 2002, 25:2133-2140.
66. Weng J., Li Y., Xu W., et al. Effect of intensive insulin therapy on beta-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomised parallel-group trial. Lancet 2008, 371:1753-1760.
67. Ryan E.A., Imes S., Wallace C. Short-term intensive insulin therapy in newly diagnosed type 2 diabetes. Diabetes Care 2004, 27:1028-1032.
68. Home P.D., Lagarenne P. Combined randomised controlled trial experience of malignancies in studies using insulin glargine. Diabetologia 2009, 52:2499-2506.
69. Dejgaard A., Lynggaard H., Rastam J., Krogsgaard T.M. No evidence of increased risk of malignancies in patients with diabetes treated with insulin detemir: a meta-analysis. Diabetologia 2009, 52:2507-2512.
70. Jennings A.M., Wilson R.M., Ward J.D. Symptomatic hypoglycemia in NIDDM patients treated with oral hypoglycemic agents. Diabetes Care 1989, 12:203-208.
71. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008, 358:2545-2559. The Action to Control Cardiovascular Risk in Diabetes Study Group.
72. Patel A., MacMahon S., Chalmers J., et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008, 358:2560-2572. ADVANCE Collaborative Group.
73. Anderson J.H., Brunelle R.L., Keohane P., et al. Mealtime treatment with insulin analog improves postprandial hyperglycemia and hypoglycemia in patients with non-insulin-dependent diabetes mellitus. Arch Intern Med 1997, 157:1249-1255.
74. Anderson J.H., Brunelle R.L., Koivisto V.A., et al. Improved mealtime treatment of diabetes mellitus using an insulin analogue. Clin Ther 1997, 19:62-72.
75. Yki-Järvinen H., Dressler A., Ziemen M. Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. Diabetes Care 2000, 23:1130-1136.
76. Fritsche A., Schweitzer M.A., Haring H.U., et al. Glimepiride combined with morning insulin glargine, bedtime neutral protamine hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes. A randomized, controlled trial. Ann Intern Med 2003, 138:952-959.
77. Janka H.U., Plewe G., Riddle M.C., et al. Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes. Diabetes Care 2005, 28:254-259.
78. Horvath K., Jeitler K., Berghold A., et al. A long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus (review). Cochrane Database Syst Rev 2007, 2:CD005613.
79. Monami M., Marchionni N., Mannucci E. Long-acting insulin analogues versus NPH human insulin in type 2 diabetes: a meta-analysis. Diabetes Res Clin Pract 2008, 81:184-189.
80. Holman R.R., Paul S.K., Bethel M.A., et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008, 359:1577-1589.
81. Hoffmann J., Spengler M. Efficacy of 24-week monotherapy with acarbose, glibenclamide, or placebo in NIDDM patients. The Essen Study. Diabetes Care 1994, 17:561-566.
82. Holman R.R., Cull C.A., Turner R.C. A randomized double-blind trial of acarbose in type 2 diabetes shows improved glycemic control over 3 years (U.K. Prospective Diabetes Study 44). Diabetes Care 1999, 22:960-964.
83. Wright A., Burden A.C., Paisey R.B., et al. Sulfonylurea inadequacy: efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the U.K. Prospective Diabetes Study (UKPDS 57). Diabetes Care 2002, 25:330-336.
84. Ohkubo Y., Kishikawa H., Araki E., et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 1995, 28:103-117.
85. Haak T., Tiengo A., Draeger E., et al. Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes. Diabetes Obes Metab 2005, 7:56-64.
86. Harrower A. Gliclazide modified release: from once-daily administration to 24 hour blood glucose control. Metabolism 2000, 49(10 suppl 2):7-11.
87. Tessier D., Dawson K., Tétrault J.P., et al. Glibenclamide vs gliclazide in type 2 diabetes of the elderly. Diabet Med 1994, 11:974-980.
88. Schade D.S., Jovanovic L., Schneider J. A placebo-controlled, randomized study of glimepiride in patients with type 2 diabetes mellitus for whom diet therapy is unsuccessful. J Clin Pharmacol 1998, 38:636-641.
89. Dills D.G., Schneider J. Clinical evaluation of glimepiride versus glyburide in NIDDM in a double-blind comparative study. Horm Metab Res 1996, 28:426-429.
90. Holstein A., Plaschke A., Egberts E.H. Lower incidence of severe hypoglycaemia in patients with type 2 diabetes treated with glimepiride versus glibenclamide. Diabetes Metab Res Rev 2001, 17:467-473.
91. Black C., Donnelly P., McIntyre L., et al. Meglitinide analogues for type 2 diabetes mellitus. Cochrane Database Syst Rev 2007, 2:CD004654.
92. Wolffenbuttel B.H.R., Landgraf R. A 1-year multicenter randomized double-blind comparison of repaglinide and glyburide for the treatment of type 2 diabetes. Diabetes Care 1999, 22:463-467.
93. Damsbo P., Clauson P., Marbury T.C., et al. A double-blind randomized comparison of meal-related glycemic control by repaglinide and glyburide in well-controlled type 2 diabetic patients. Diabetes Care 1999, 22:789-794.
94. Schernthaner G., Grimaldi A., Di Mario U., et al. GUIDE study: double-blind comparison of once-daily gliclazide MR and glimepiride in type 2 diabetic patients. Eur J Clin Invest 2004, 34:535-542.
95. Garber A.J., Duncan T.G., Goodman A.M., et al. Efficacy of metformin in type II diabetes: results of a double-blind, placebo-controlled, dose-response trial. Am J Med 1997, 103:491-497.
96. de Jager J., Kooy A., Lehert P., et al. Long term treatment with metformin in patients with type 2 diabetes and risk of vitamin B-12 deficiency: randomised placebo controlled trial. BMJ 2010, 340:c2198.
97. Aronoff S., Rosenblatt S., Braithwaite S., et al. Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. Diabetes Care 2000, 23:1605-1611.
98. Raskin P., Rappaport E.B., Cole S.T., et al. Rosiglitazone short-term monotherapy lowers fasting and post-prandial glucose in patients with type II diabetes. Diabetologia 2000, 43:278-284.
99. Nolan J.J., Jones N.P., Patwardhan R., et al. Rosiglitazone taken once daily provides effective glycaemic control in patients with type 2 diabetes mellitus. Diabet Med 2000, 17:287-294.
100. Lebovitz H.E., Dole J.F., Patwardhan R., et al. Rosiglitazone monotherapy is effective in patients with type 2 diabetes. J Clin Endocrinol Metab 2001, 86:280-288.
101. Fonseca V., Rosenstock J., Patwardhan R., et al. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial. JAMA 2000, 283:1695-1702.
102. Kipnes M.S., Krosnick A., Rendell M.S., et al. Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, placebo-controlled study. Am J Med 2001, 111:10-17.
103. Einhorn D., Rendell M., Rosenzweig J., et al. Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. Clin Ther 2000, 22:1395-1409.
104. Yale J.-F., Valiquett T.R., Ghazzi M.N., et al. The effect of a thiazolidinedione drug, troglitazone, on glycemia in patients with type 2 diabetes mellitus poorly controlled with sulfonylurea and metformin. A multicenter, randomized, double-blind, placebo-controlled trial. Ann Intern Med 2001, 134:737-745.
105. Miles J.M., Leiter L., Hollander P., et al. Effect of orlistat in overweight and obese patients with type 2 diabetes treated with metformin. Diabetes Care 2002, 25:1123-1128.
106. Kelley D.E., Bray G.A., Pi-Sunyer F.X., et al. Clinical efficacy of orlistat therapy in overweight and obese patients with insulin-treated type 2 diabetes: a 1-year randomized controlled trial. Diabetes Care 2002, 25:1033-1041.
107. Hollander P.A., Elbein S.C., Hirsch I.B., et al. Role of orlistat in the treatment of obese patients with type 2 diabetes. A 1-year randomized double-blind study. Diabetes Care 1998, 21:1288-1294.
108. Singh S., Loke Y.K., Furberg C.D. Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. JAMA 2007, 298:1189-1195.
109. Lewis J.D., Ferrara A., Peng T., et al. Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study. Diabetes Care 2011, 34:916-922.
110. Jacob S., Rabbia M., Meier M.K., Hauptman J. Orlistat 120 mg improves glycaemic control in type 2 diabetic patients with or without concurrent weight loss. Diabetes Obes Metab 2009, 11:361-371.
111. Berne C. A randomized study of orlistat in combination with a weight management programme in obese patients with Type 2 diabetes treated with metformin. Diabet Med 2004, 22:612-618.